The federal government has asked Australia’s medical and vaccine regulators to urgently consider the European Medicines Agency’s finding of a possible link between the Oxford/AstraZeneca COVID vaccine and rare blood clots.
This follows reports over recent weeks of blood clots in a small number of people around the world who had received the AstraZeneca vaccine, including one man who was hospitalised in Melbourne.
Scientists have termed the condition “vaccine induced prothrombotic immune thrombocytopenia” (VIPIT). But what does this actually mean, how significant is the risk, and what are the implications for Australia’s vaccine rollout — which is currently relying predominantly on the AstraZeneca jab?
A Paucity of Platelets
As indicated by its name, VIPIT is a form of something called thrombocytopenia.
Thrombocytopenia is a condition whereby the numbers of thrombocytes (very small blood particles, or platelets) are markedly reduced. Platelets form clots to stop bleeding, so when you don’t have enough platelets in your blood, your body can’t form clots. This can lead to excessive bleeding.
The condition has a genetic component, but can also arise from more than 300 common medicines, including penicillin and certain pain killers. Quinine, which is added to tonic water for flavour, can also very rarely cause thrombocytopenia.
The symptoms of VIPIT can include severe headaches, abdominal pain, seizures and visual changes. These are similar to the symptoms of thrombocytopenia unrelated to the vaccine.
In rare cases of thrombocytopenia, clots can develop in the vessels draining blood from the brain. The European Medicines Agency said it had received reports of 169 cases of brain blood clots in people who had been vaccinated with the AstraZeneca shot.
In severe cases, thrombocytopenia can be fatal. There have been deaths from blood clots reportedly associated with the AstraZeneca vaccine, including 19 in the United Kingdom.
VIPIT appears to present 4-20 days after vaccination, and so far, the issue has been largely associated with women under the age of 65.
So how could this vaccine potentially cause thrombocytopenia? The “prothrombotic immune” part of the name denotes it’s caused by an over-activation of the immune system, which gives us a clue.
Platelets and COVID-19
The AstraZeneca vaccine prompts cells to make a specific part of SARS-CoV-2 (the virus that causes COVID-19), called the spike protein, which the virus uses to attach to cells when infecting us.
The vaccine stimulates our immune system to generate antibodies against the spike protein, which then primes the body to mount an immune response against SARS-CoV-2, if it encounters the virus in the future.
But in some people, the AstraZeneca vaccine seems to produce antibodies that react with platelets, making them stick together, leading the blood to clot. This in turn reduces circulating platelet numbers, and hence the thrombocytopenia.
These antibodies are similar to those found in some people on a blood thinning drug called heparin. The immune response to heparin generates antibodies that bind to platelets. This can lead to blood clots in some people, called heparin induced thrombocytopenia. As many as one in 20 patients receiving heparin develop thrombocytopenia.
Keeping in mind we’re yet to establish cause and effect, it’s a possibility that the biological mechanism by which we believe heparin leads to thrombocytopenia could be the same biological mechanism by which the AstraZeneca vaccine might.
How Common is It?
Naturally occurring thrombocytopenia affects about one in 30,000 adults a year in the United States.
As for the suspected vaccine-induced kind, according to data collated by the Thrombosis and Haemostasis Society of Australia and New Zealand, VIPIT is as rare as one in 500,000 people. But the society notes the data are incomplete.
Different countries have reported different rates. Norway, for example, has so far reported one in 25,000 vaccinated adults under the age of 65 have experienced low platelet counts, bleeding, and widespread thromboses (blood clots).
Of course, the possibility that some of these cases of thrombocytopenia may have occurred regardless of the vaccine makes understanding vaccine-induced cases more complicated. But taken together, thrombocytopenia appears to be more common in the general population than among those who have been vaccinated.
As we continue to vaccinate the world, it’s likely small subsets of people will continue to experience this complication. Whether we can establish a causal link between the AstraZeneca vaccine and thrombocytopenia is subject to continued investigation.
Be Aware, But Not Alarmed
Amid this ongoing investigation, some countries, such as Norway, have paused their rollouts of the AstraZeneca vaccine. Others have restricted use of the vaccine in certain groups, like Canada, which is using it only for adults older than 55, who may have higher risks from COVID and lower risk of blood clots. Meanwhile, the UK has pledged to make other vaccine options available for younger people.
We will wait to see how the Australian experts respond. But for the general adult population, we agree with the current guidance from bodies including the European Medicines Agency and the World Health Organization that the benefits of the AstraZeneca vaccine outweigh the risks.
That said, it’s not unreasonable to be cautious. You should monitor for these symptoms up to 28 days after receiving the jab:
- pain in the chest or stomach
- swelling or coldness in the leg
- severe or worsening headache
- blurred vision
- persistent bleeding
- multiple small bruises, reddish or purplish spots, or blood blisters under the skin.
If you’re experiencing any of these symptoms and you’re concerned, seek medical advice.
ABOUT THE AUTHORS
Anthony Zulli, Associate professor, Victoria University. Dr Zulli joined Victoria University after finishing his NHMRC Peter Doherty Fellowship in 2009 (2006-2009, University of Melbourne, Austin Health). Dr Zulli’s research focuses on the mechanisms that cardiovascular disease risk factors (homocysteine/cholesterol) cause endothelial dysfunction. His research has an emphasis on the nitric oxide pathway, oxidative stress and the renin-angiotensin system, and has a recent interest on reducing kidney disease caused by cancer treatments. Dr Zulli has been funded by the National Heart Foundation and NHMRC, as well as internal VU grant schemes.
Maja Husaric, Senior Lecturer; MD, Victoria University. Dr Maja Husaric is a trained Medical Doctor who works as an academic at Victoria University. Dr Husaric has an extensive background in on-field medical experience as a GP and in ICU, as an anesthetist during Balkan conflict in a war zone. She moved to academia in 2000 and has been focused on clinical medical education for the health professionals at Unitec, New Zealand, and Victoria University Australia. For last decade, Dr Husaric’s has been focusing research on photobiomodulation therapy as one of the potential non-invasive, non-pharmacological avenues of disease treatment that will be required to sustain the increasing burden of inflammatory diseases as the population ages. Since 2017 she has been co-leading the Victoria University photobiomodulation research team, pioneering a novel phototherapeutic and photobiology research laboratory.
Maximilian de Courten, Professor in Global Public Health and Director of the Mitchell Institute, Victoria University. Prof. Maximilian de Courten is a Global Public Health expert with over 25 years’ experience in health interventions ranging from clinical trials to translation of this research into population-based approaches. His research focus is Global Health and disease surveillance in the area of chronic diseases. He has worked in a range of different organizations, such as large governmental research institutes (the NIH in the US), inter- governmental institutions (WHO), private research institutions and academia (University of Copenhagen – most recently – Monash and Deakin University, University of Bern).
Vasso Apostolopoulos, Professor of Immunology and Associate Provost, Research Partnerships, Victoria University. Over 25 years experience in research in the area of vaccines and drugs for cancer and chronic diseases with translational focus. In addition, extensive clinical research background, translating research to clinical trials. Multidisciplinary research expertise, in the areas of, immunology, crystallography, medicinal chemistry, biochemistry, crystallography, clinical research and drug development. Main focus is treating diseases with an immunological focus. Areas of research include: cancer, type-1 diabetes, type-2 diabetes, multiple sclerosis, mental health, drug addiction, infectious diseases including the recent SARS-CoV-2 virus which causes COVID-19.
This article is courtesy of The Conversation.